Random-Effects Linear Modeling and Sample Size Tables for Two Special Crossover Designs of Average Bioequivalence Studies: The Four-Period, Two-Sequence, Two-Formulation and Six-Period, Three-Sequence, Three-Formulation Designs Francisco J. DiazMichel J. BergMichael Privitera Leading Article 02 October 2013 Pages: 1033 - 1043
Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders Philip N. Patsalos Review Article 22 June 2013 Pages: 1045 - 1061
Clinical Pharmacokinetics and Pharmacodynamics of Erythropoiesis-Stimulating Agents Sameer DoshiWojciech KrzyzanskiJuan José Pérez-Ruixo Review Article 03 August 2013 Pages: 1063 - 1083
Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling Zoe E. BarterGeoffrey T. TuckerKaren Rowland-Yeo Original Research Article 02 July 2013 Pages: 1085 - 1100
Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours Sven WindMarion SchmidPeter Stopfer Original Research Article 28 June 2013 Pages: 1101 - 1109
Neutrophil Dynamics in Peritoneal Carcinomatosis Patients Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Oxaliplatin Carlos Pérez-RuixoBelén ValenzuelaJuan José Pérez-Ruixo Original Research Article 05 July 2013 Pages: 1111 - 1125
Amikacin Maturation Model as a Marker of Renal Maturation to Predict Glomerular Filtration Rate and Vancomycin Clearance in Neonates Wei ZhaoValérie BiranEvelyne Jacqz-Aigrain Short Communication 12 September 2013 Pages: 1127 - 1134